Redmond, Washington, USA – May 21, 2026
SystImmune, Inc. announced that multiple clinical and late-stage development data sets from its expanding antibody-drug conjugate (ADC) oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago. The presentations include major updates on izalontamab brengitecan (iza-bren) and several next-generation ADC programs targeting difficult-to-treat cancers including triple-negative breast cancer, esophageal cancer, small-cell lung cancer, ovarian cancer, and HER2-positive tumors. The data highlight SystImmune’s growing role in precision oncology and reinforce the company’s strategy of rapidly advancing innovative biologic therapies into late-stage clinical development.
Phase III Data Strengthens iza-bren Development Program
One of the most closely watched presentations at ASCO 2026 will feature late-breaking Phase III clinical trial results evaluating iza-bren, a potentially first-in-class EGFRxHER3 bispecific ADC, in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). The randomized study compared iza-bren with physician’s choice chemotherapy in China and represents a major milestone in the therapy’s global development program.
Additional Phase III data will also be presented for patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC), further expanding the clinical potential of the therapy across multiple aggressive tumor types. SystImmune stated that iza-bren is jointly being developed with Bristol Myers Squibb outside China under an exclusive licensing and collaboration agreement, highlighting growing international interest in the company’s ADC platform.
Researchers explained that iza-bren combines dual targeting of EGFR and HER3, two important drivers of cancer growth and survival, with a proprietary topoisomerase I inhibitor payload designed to induce targeted cytotoxicity inside tumor cells. By simultaneously blocking tumor signaling pathways and delivering potent chemotherapy directly to cancer cells, the therapy aims to improve efficacy while minimizing systemic toxicity.
Advertisement
Novel ADC Programs Show Promise Across Multiple Tumor Types
Beyond iza-bren, SystImmune will also present new clinical data from several emerging ADC programs that demonstrate the breadth of its proprietary brengitecan platform. One of the featured studies involves BL-M14D1, a novel DLL3-directed ADC being evaluated in patients with small-cell lung cancer (SCLC), neuroendocrine carcinoma, and other advanced solid tumors.
The company is also presenting Phase II results for T-Bren (BL-M07D1), a HER2-targeted ADC being investigated in recurrent or metastatic ovarian cancer as well as in HER2-positive advanced breast cancer. Additional studies are evaluating T-Bren both as a monotherapy and in combination with pertuzumab, supporting the growing trend toward combination biologic strategies in precision oncology.
Another important program includes BL-M05D1, a novel Claudin 18.2-directed ADC targeting tumors expressing the Claudin18.2 protein, including gastric and pancreatic cancers. Researchers believe Claudin18.2 has become one of the most promising emerging oncology biomarkers due to its high expression in several aggressive gastrointestinal tumors.
ADC Innovation Continues to Transform Cancer Therapy
Industry analysts view SystImmune’s broad ASCO presence as evidence of the rapidly growing importance of ADC technologies in cancer treatment. ADCs combine the precision targeting capabilities of monoclonal antibodies with the tumor-killing power of chemotherapy payloads, allowing more selective delivery of anticancer agents directly into malignant cells.
SystImmune executives stated that the expanding clinical pipeline demonstrates both the scalability and flexibility of the company’s proprietary ADC platform. By pairing different targeting antibodies with the brengitecan payload technology, the company aims to create highly specialized therapies tailored to distinct tumor biomarkers and cancer subtypes.
The ASCO 2026 presentations also reinforce the increasing global competition within the oncology biologics sector, where biotechnology companies are racing to develop next-generation targeted therapies capable of improving survival outcomes in difficult-to-treat cancers. With several late-stage programs advancing simultaneously, SystImmune is positioning itself as an emerging player in the rapidly evolving ADC therapeutics market.
Source: SystImmune press release
